Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966527 | 0.71 | GPR3 (0.33) | PLCG1MEN1KMT2ANOX1GPR3 | |
| SCHEMBL3536271 | 0.71 | GPR3 (0.33) | PLCG1MEN1KMT2ANOX1GPR3 | |
| SCHEMBL255968 | 0.67 | GPR3 (0.46) | PLCG1KEAP1MEN1KMT2ANOX1 | |
| SCHEMBL88679 | 0.67 | PLCG1 (0.48) | PLCG1KEAP1MEN1KMT2ANOX1 | |
| SCHEMBL1992607 | 0.66 | CA12 (0.38) | PLCG1KEAP1MEN1KMT2ANOX1 | |
| SCHEMBL2918638 | 0.66 | GPR3 (0.36) | PLCG1MEN1KMT2ANOX1GPR3 | |
| SCHEMBL2589655 | 0.64 | CD44 (0.45) | PLCG1KEAP1MEN1KMT2ANOX1 | |
| Hydrochloric Acid SCHEMBL5849050 | 0.63 | CD44 (0.44) | PLCG1KEAP1MEN1KMT2ANOX1 | |
| SCHEMBL519190 | 0.62 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL2998 | 0.61 | HTR2C (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149992-A1 | IMAGING COMPOUNDS FOR DETECTING OR IMAGING SENESCENT CELLS | UNIVERSITY OF DUNDEE (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-11969473-B2 | Multifunctional conjugates | E.P.O.S IASIS RESEARCH AND DEVELOPMENT LIMITED (CY) | 2024-04-30 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2024-04-04 | — | — | US | disclosed |
| WO-2024003557-A1 | SULFOXIMINES AS INHIBITORS OF LYSYL OXIDASE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023233148-A1 | CANCER THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, (GB) | 2023-12-07 | — | — | WO | disclosed |
| EP-4277631-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | Liverpool School of Tropical Medicine (GB) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| EP-2516449-A1 | PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE | Cephalon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | CEPHALON INC. (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012125603-A1 | MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2011087822-A1 | PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969473-B2 | Multifunctional conjugates | MKI67, ACP3, CD44 | PLCG1 635/4885KEAP1 130/4885MEN1 250/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | PLCG1 2030/4885KEAP1 1805/4885MEN1 484/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | PLCG1 2901/4885KEAP1 316/4885MEN1 196/4885 |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | PWWP2B, WARS1, PNPO | PLCG1 206/4885KEAP1 1777/4885MEN1 4437/4885 |
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | PSMB1, PSMB11, PSMB7 | PLCG1 3503/4885KEAP1 198/4885MEN1 774/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | PLCG1 2030/4885KEAP1 1805/4885MEN1 484/4885 |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | AQP3, AQP1, AQP4 | PLCG1 3799/4885KEAP1 1391/4885MEN1 2966/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | PLCG1 589/4885KEAP1 285/4885MEN1 3470/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | PLCG1 2717/4885KEAP1 390/4885MEN1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.